Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Hiroki AkiyamaHagop KantarjianElias JabbourGhayas IssaFadi G HaddadNicholas J ShortShimin HuJo IshizawaMichael AndreeffKoiji SasakiPublished in: International journal of hematology (2024)
Outcomes of 3q26.2/MECOM-rearranged CML are poor despite the availability of multiple BCR::ABL1 tyrosine kinase inhibitors (TKIs). Third-generation TKIs in combination with novel agents and possible allo-SCT could be considered given the poor outcomes and resistance to second-generation TKIs.